Related Experiment Videos
[Dmt(1)]DALDA analogues modified with tyrosine analogues at position 1
Yunxin Cai1, Dandan Lu1, Zhen Chen1
1School of Pharmacy, Nanjing Medical University, 101 Longmian Avenue, Nanjing 211166, China.
Bioorganic & Medicinal Chemistry Letters
|June 16, 2016
Summary
New peptide analogues targeting μ opioid receptors show enhanced antioxidant activity for neuropathic pain treatment. These compounds, derived from [Dmt(1)]DALDA, offer potential as novel therapeutic agents.
Area of Science:
- Medicinal Chemistry
- Neuroscience
- Pharmacology
Background:
- [Dmt(1)]DALDA is a potent μ opioid agonist with mitochondria-targeted antioxidant properties.
- Neuropathic pain is a debilitating condition often requiring novel treatment strategies.
Purpose of the Study:
- To synthesize and evaluate novel analogues of [Dmt(1)]DALDA by modifying the tyrosine residue.
- To assess the μ opioid receptor binding affinity and antioxidant activity of these new analogues.
- To identify potential drug candidates for neuropathic pain.
Main Methods:
- Synthesis of peptide analogues replacing 2',6'-dimethyltyrosine (Dmt) with various 2',6'-dialkylated tyrosine analogues (Tmt, Emt, Imt, Det).
- Evaluation of μ opioid receptor binding affinities.
- Assessment of antioxidant activity using the DPPH radical-scavenging capacity assay.
Main Results:
- All synthesized analogues were selective μ opioid agonists.
- Tmt(1)-, Emt(1)-, and Det(1)-analogues exhibited subnanomolar μ opioid receptor binding affinities.
- Tmt(1)- and Emt(1)-analogues demonstrated improved antioxidant activity compared to the parent [Dmt(1)]DALDA peptide.
Conclusions:
- Modified [Dmt(1)]DALDA analogues retain μ opioid agonist activity and exhibit enhanced antioxidant properties.
- The Tmt(1)- and Emt(1)-analogues are promising candidates for further development in neuropathic pain treatment.
- These findings highlight the potential of rationally designed peptides for managing complex pain conditions.